2016 Annual Meeting | Clinical Research: Drug Development and Clinical Trials

Date Friday 04/15/16

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Wendy R. Galpern, MD, PhD, FAAN

Topic(s)

Learning Objectives Participants should have an increased understanding of the steps involved in drug discovery and development, the challenges inherent to each stage, and clinical trial design considerations and regulatory perspectives.

CME Available 0.00 credit

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Didactic, Interactive, Audience Participation

Event Timeline
03:30 PM - 03:35 PM		Introduction Wendy R. Galpern, MD, PhD, FAAN, Kwan-hong C. Min, MD, PhD
03:35 PM - 03:55 PM		Regulatory Considerations Lei Xu, MD
03:55 PM - 04:15 PM		Clinical Trial Design Considerations Christopher Coffey, PhD, FAAN
04:15 PM - 04:35 PM		Late Stage Development: Decisions and Challenges Karl D. Kieburtz, MD
04:35 PM - 04:55 PM		Early Stage Development: Decisions and Challenges Gilmore N. O'Neill, MD, MB, MRCPI
04:55 PM - 05:30 PM		Discussion; Questions and Answers

Faculty Disclosures
Karl D. Kieburtz, MD	Dr. Kieburtz has received personal compensation for serving as an employee of Clintrex Research Corporation. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Kieburtz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Kieburtz has stock in Clintrex Research Corp. Dr. Kieburtz has stock in Hoover Brown. An immediate family member of Dr. Kieburtz has stock in Hoover Brown. Dr. Kieburtz has stock in Safe Therapeutics. The institution of Dr. Kieburtz has received research support from NIH. The institution of Dr. Kieburtz has received research support from Michae J Fox Foundation.
Kwan-hong C. Min, MD, PhD	No disclosure on file
Christopher Coffey, PhD, FAAN	Dr. Coffey has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Coffey has received research support from NIH. The institution of Dr. Coffey has received research support from Michael J Fox Foundation.
Lei Xu, MD	No disclosure on file
Gilmore N. O'Neill, MD, MB, MRCPI	No disclosure on file
Wendy R. Galpern, MD, PhD, FAAN	No disclosure on file

��ɫ��

��ɫ��